Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia
出版年份 2016 全文链接
标题
Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia
作者
关键词
Imatinib, Chronic Myeloid Leukaemia, Pulmonary Arterial Hypertension, Dasatinib, Acute Lymphoblastic Leukaemia
出版物
DRUGS
Volume 77, Issue 1, Pages 85-96
出版商
Springer Nature
发表日期
2016-12-28
DOI
10.1007/s40265-016-0677-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
- (2016) Neil P. Shah et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
- (2016) Charles A. Schiffer et al. CANCER
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
- (2016) J L Steegmann et al. LEUKEMIA
- Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
- (2015) Neil P. Shah et al. AMERICAN JOURNAL OF HEMATOLOGY
- Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
- (2015) Masatomo Miura BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia
- (2015) Toshihiko Ando et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
- (2015) T P Hughes et al. LEUKEMIA
- Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
- (2015) Jun Imagawa et al. Lancet Haematology
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Large granular lymphocytosis during dasatinib therapy
- (2013) Zhi-Yuan Qiu et al. CANCER BIOLOGY & THERAPY
- Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up
- (2013) Shin Fujisawa et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
- (2013) Charles T. Chuah et al. LEUKEMIA & LYMPHOMA
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
- (2012) S Mustjoki et al. LEUKEMIA
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
- (2010) Fabio P. S. Santos et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study
- (2010) Giuseppe Saglio et al. CANCER
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
- (2009) A. Quintas-Cardama et al. BLOOD
- Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
- (2009) H. Kantarjian et al. BLOOD
- Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
- (2009) Kimmo Porkka et al. CANCER
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
- (2008) Neil P. Shah et al. CANCER CELL
- Metabolism and Disposition of Dasatinib after Oral Administration to Humans
- (2008) L. J. Christopher et al. DRUG METABOLISM AND DISPOSITION
- Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
- (2008) D. H. Kim et al. HAEMATOLOGICA
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
- (2008) Shaoguang Li LEUKEMIA & LYMPHOMA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now